Akoya Biosciences Introduces PhenoCode Discovery Panels to Simplify PhenoCycler-Fusion Workflow
Akoya Biosciences, Inc. (Nasdaq: AKYA) has launched the PhenoCode Discovery Panels at the AACR 2023 Annual Meeting in Orlando, aimed at advancing cancer research. These panels facilitate the analysis of tumors and their microenvironment by providing ready-to-use biomarker combinations for immune profiling and tissue architecture assessment. They significantly reduce assay development time, accelerating spatial discovery by up to three times compared to traditional workflows. The company plans to expand its product offerings with more protein biomarker panels throughout 2023 and 2024, along with launching RNA panels in the latter half of 2023. Akoya's innovations aim to streamline workflows for researchers and enhance the capabilities of the PhenoCycler-Fusion platform.
- Launch of PhenoCode Discovery Panels simplifying workflows for cancer research.
- Accelerates spatial discovery by 3x compared to standard workflows.
- Plans to introduce additional protein biomarker panels in 2023 and 2024.
- Expected launch of RNA panels in H2 2023.
- None.
- Modular panel design sets foundation for continued expansion of applications on the PhenoCycler®-Fusion system
- First protein panel commercially available at AACR 2023 Annual Meeting and first RNA panel to launch in H2 2023
MARLBOROUGH, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the launch of PhenoCode™ Discovery Panels, which simplify spatial biology workflows performed on the company’s PhenoCycler-Fusion platform, at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Florida, April 14-19, 2023.
PhenoCode Discovery Panels are designed to advance cancer research by enabling thorough interrogation of tumors and the surrounding tumor microenvironment. Each of the ready-to-use, modular panels include biomarkers that can answer key biological questions related to immune profiling, lymphocyte profiling, tissue architecture, and immune activation and proliferation. The panels can be used on their own or combined to explore increasingly complex questions and significantly scale the “plex” of discovery in a stepwise fashion. Upfront assay development and validation time is significantly reduced, accelerating spatial discovery by 3x compared to standard workflows.
“The PhenoCode Discovery Panels further streamline and simplify the workflow on the PhenoCycler-Fusion System, offering new avenues of exploration for existing customers and paving the way for researchers who want to leverage this powerful technology for the first time,” said Brian McKelligon, CEO of Akoya. “These panels are an important part of the spatial biology ecosystem which Akoya has established and continues to expand. Our vision is to offer a comprehensive suite of panels for multiple applications. We expect to launch additional PhenoCode Discovery Panels for protein biomarkers throughout 2023 and 2024, and introduce panels for RNA in the second half of this year.”
The PhenoCode Discovery Panels will be highlighted at booth #1713 at AACR. More than a dozen posters describing use of the company’s spatial biology solutions will be shared at AACR by Akoya scientists and collaborators.
Akoya scientists and collaborators will also share spatial biology case studies on the use of high plex spatial phenotyping to reveal new insights into tumor progression and treatment response in a spotlight session at AACR. Details of the presentation are as follows:
Date/Time: Monday, April 17, 2023, 10:00 AM
Location: Spotlight Theater C
Speakers:
- Rajkumar Savai, PhD, Professor of Lung Microenvironmental Niche in Cancerogenesis, Max-Planck-Institute for Heart and Lung Research and Institute for Lung Health (ILH)
- Jasmine Plummer, PhD Founding Director, Center for Spatial Omics, St. Jude Children’s Research Hospital
- Oliver Braubach, PhD, Director of Applications, Akoya Biosciences
More details about Akoya’s AACR activities and poster presentations can be found here.
Forward-Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, expected timing of planned product launches, our expectations about the potential of our products and services and other matters regarding our business strategies and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include risks and uncertainties related to the development of our planned products and services, our ability to execute on our plans and expectations and other risks described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit www.akoyabio.com.
Investor Contact:
Priyam Shah
Sr. Director, Investor Relations
Akoya Biosciences, Inc.
investors@akoyabio.com
Media Contact:
Christine Quern
(617) 650-8497
media@akoyabio.com
FAQ
What are the PhenoCode Discovery Panels launched by Akoya Biosciences?
When was the PhenoCode Discovery Panels launched?
How do the PhenoCode Discovery Panels benefit cancer research?
What future products does Akoya plan to launch related to the PhenoCode panels?
What is Akoya's stock symbol?
